Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-1 in Advanced Solid Tumors
NCT03490669Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of AZD0171 in solid tumor (advanced stage), pancreatic cancer (PC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and Tolerability of MSC-1 at 6 months and Preliminary Anti-tumor Activity at 6 months. Started May 2018; status: completed.
02
Drugs
AZD0171
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT03490669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490669.